<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481660</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258B2302</org_study_id>
    <secondary_id>2017-003960-11</secondary_id>
    <nct_id>NCT03481660</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema</brief_title>
  <acronym>KITE</acronym>
  <official_title>A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment
      of patients with visual impairment due to diabetic macular edema (DME).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 2-year, randomized, double-masked, multicenter, active controlled study, consenting
      patients will be randomized in a 1:1 ratio to one of the two treatment arms and attend 28
      planned visits.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 29, 2018</start_date>
  <completion_date type="Anticipated">July 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in best-corrected visual acuity (BCVA) at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>BCVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in BCVA over the period Week 40 through Week 52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at q12w up to Weeks 52 and 100</measure>
    <time_frame>Up to Week 100</time_frame>
    <description>Positive treatment status is defined as IVT injections per planned dosing regimen [every 12 weeks (q12w)]. This outcome measure is pre-specified for brolucizumab treatment arm only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at q12w up to Week 52 within those patients that qualified for q12w at Week 36</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This outcome measure is pre-specified for brolucizumab treatment arm only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA at each visit up to Week 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in BCVA over the period Week 4 to Week 52/100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in BCVA over the period Week 20 to Week 52/100 and Week 28 to Week 52/100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain in BCVA of ≥5, ≥10, and ≥15 ETDRS letters from baseline to each post-baseline visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve gain in BCVA of ≥5, ≥10, and ≥15 ETDRS letters from baseline (or reaching a score of 84 or more)</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss in BCVA of ≥5, ≥10, and ≥15 ETDRS letters from baseline to each post-baseline visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute BCVA ≥73 ETDRS letters at each post-baseline visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at q12w up to Week 64 (after three q12w- treatment intervals)</measure>
    <time_frame>Up to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at q12w up to Week 64 (after three q12w- treatment intervals), within those patients that qualified for q12w at Week 36</measure>
    <time_frame>Up to Week 64</time_frame>
    <description>This outcome measure is pre-specified for brolucizumab treatment arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at q12w/q16w up to Week 100, within those patients that qualified for q12w at Week 36</measure>
    <time_frame>Up to Week 100</time_frame>
    <description>This outcome measure is pre-specified for brolucizumab treatment arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with disease activity at Week 32 (eg ≥5 letters loss in BCVA compared to Week 28)</measure>
    <time_frame>Week 28, Week 32</time_frame>
    <description>This outcome measure is pre-specified for brolucizumab treatment arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained on q16w up to Week 100 within the patients on q12 at Week 68 and on q16w at Week 76</measure>
    <time_frame>Up to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients re-assigned and maintained on q12w up to Week 100 within the patients on q8w at Week 68 and on q12w at Week 80</measure>
    <time_frame>Up to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with injections per planned dosing regimen (every 8, 12 or 16 weeks)</measure>
    <time_frame>Up to Week 100</time_frame>
    <description>This outcome measure is pre-specified for brolucizumab treatment arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central subfield thickness (CSFT) at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by Spectral Domain Optical Coherence Tomography (SD-OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in CSFT over the period Week 40 through Week 52 / Week 88 through Week 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in CSFT over the period Week 4 to Week 52 / 96</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>Assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient status regarding normal CSFT thickness (&lt;280 microns) at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central subfield thickness-neurosensory (CSFTns) at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in CSFTns over the period Week 40 through Week 52 / Week 88 through Week 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in CSFTns over the period Week 4 to Week 52 / 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with presence of subretinal fluid (SRF) at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT, angiography, and/or color fundus photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with presence of intraretinal fluid (IRF) at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT, angiography, and/or color fundus photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with simultaneous absence of SRF and IRF at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed by SD-OCT, angiography, and/or color fundus photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with presence of leakage on fluorescein angiography (FA) at Weeks 52 and 100</measure>
    <time_frame>Up to Week 100</time_frame>
    <description>Assessed by fluorescein angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) score at each assessment visit</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>The Diabetic Retinopathy Disease Severity Scale measures the 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with progression to proliferative diabetic retinopathy (PDR) as assessed by ETDRS-DRSS Score of at least 61 by Week 52 and Week 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>ETDRS-DRSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient reported outcomes (VFQ-25) total and subscale scores up to Week 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic brolucizumab/aflibercept concentration</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) status</measure>
    <time_frame>Up to Week 100</time_frame>
    <description>Blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change from baseline in BCVA from the period Week 88 to 100</measure>
    <time_frame>Baseline up to Week 100</time_frame>
    <description>Assessed with ETDRS visual acuity testing charts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Brolucizumab 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept 2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brolucizumab</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>Brolucizumab 6 mg</arm_group_label>
    <other_name>RTH258, ESBA1008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>Aflibercept 2 mg</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent before any assessment

          -  Patients with type 1 or type 2 diabetes mellitus and HbA1c of ≤10% at screening

          -  Medication for the management of diabetes stable within 3 months prior to
             randomization and is expected to remain stable during the course of the study

        Exclusion Criteria:

          -  Active proliferative diabetic retinopathy in the study eye

          -  Active intraocular or periocular infection or active intraocular inflammation in the
             study eye

          -  Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) &gt; 25
             millimeters mercury (mmHg)

          -  Previous treatment with anti-VEGF drugs or investigational drugs in the study eye

          -  Stroke or myocardial infarction during the 6-month period prior to baseline

          -  Uncontrolled blood pressure defined as a systolic value ≥160 mmHg or diastolic value
             ≥100 mmHg

        Other protocol-specified inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>brolucizumab</keyword>
  <keyword>aflibercept</keyword>
  <keyword>double-masked</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on ww.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

